ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Kaken Pharmaceutical Co., Ltd. ?
1
With a growth in Net Profit of 3014.02%, the company declared Outstanding results in Jun 26
- RAW MATERIAL COST(Y) Fallen by -33.57% (YoY)
- NET SALES(Q) Highest at JPY 30,154 MM
- OPERATING PROFIT(Q) Highest at JPY 11,903 MM
2
With ROE of -1.26%, it has a very attractive valuation with a 1.14 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 3.51%, its profits have fallen by -108.9%
- At the current price, the company has a high dividend yield of 0
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Kaken Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Kaken Pharmaceutical Co., Ltd. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Kaken Pharmaceutical Co., Ltd.
-100.0%
1197.98
18.69%
Japan Nikkei 225
43.52%
1.48
29.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-0.13%
EBIT Growth (5y)
-172.57%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.54
Tax Ratio
7.26%
Dividend Payout Ratio
335.97%
Pledged Shares
0
Institutional Holding
0.10%
ROCE (avg)
14.71%
ROE (avg)
8.17%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.14
EV to EBIT
-32.49
EV to EBITDA
-139.17
EV to Capital Employed
1.20
EV to Sales
1.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.69%
ROE (Latest)
-1.26%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -33.57% (YoY
NET SALES(Q)
Highest at JPY 30,154 MM
OPERATING PROFIT(Q)
Highest at JPY 11,903 MM
OPERATING PROFIT MARGIN(Q)
Highest at 39.47 %
PRE-TAX PROFIT(Q)
Highest at JPY 11,244 MM
NET PROFIT(Q)
Highest at JPY 8,440.5 MM
EPS(Q)
Highest at JPY 222.85
-10What is not working for the Company
CASH AND EQV(HY)
Lowest at JPY 108,848 MM
INTEREST(Q)
Highest at JPY 14 MM
Here's what is working for Kaken Pharmaceutical Co., Ltd.
Pre-Tax Profit
At JPY 11,244 MM has Grown at 2,655.88%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 8,440.5 MM has Grown at 3,022.24%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Net Sales
At JPY 30,154 MM has Grown at 59.82%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (JPY MM)
Net Sales
Highest at JPY 30,154 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 11,903 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 39.47 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 11,244 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 8,440.5 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 222.85
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Raw Material Cost
Fallen by -33.57% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Kaken Pharmaceutical Co., Ltd.
Interest
Highest at JPY 14 MM
in the last five periods and Increased by 7.69% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Cash and Eqv
Lowest at JPY 108,848 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Footer loading
